Background Cardiovascular disease (CVD) is a leading cause of death globally. Recently,
dipeptidyl peptidase‐4 inhibitors (DPP4i), glucagon‐like peptide‐1 receptor agonists (GLP‐
1RA) and sodium‐glucose co‐transporter‐2 inhibitors (SGLT2i) were approved for treating
people with type 2 diabetes mellitus. Although metformin remains the first‐line
pharmacotherapy for people with type 2 diabetes mellitus, a body of evidence has recently
emerged indicating that DPP4i, GLP‐1RA and SGLT2i may exert positive effects on patients …

Purpose: It has been reported that dipeptidyl peptidase-4 inhibitors (DPP-4i), glucagon-like
peptide-1 receptor agonists (GLP-1 RA), and sodium-glucose cotransporter-2 inhibitors
(SGLT-2i) have a role in modulation of inflammation associated with coronavirus disease
2019 (COVID-19). This study assessed the effect of these drug classes on COVID-19–
related outcomes. Methods: Using a COVID-19 linkable administrative database, we
selected patients aged≥ 40 years with at least 2 prescriptions of DPP-4i, GLP-1 RA, or …